Belzer MPS® – 1000mL
(UW Machine Perfusion Solution)
INDICATIONS FOR USE
Belzer MPS® (UW Machine Perfusion Solution) is intended for the in-vitro flushing and continuous hypothermic machine perfusion preservation of explanted kidneys.
Bridge to Life Ltd. recommends a volume of 1000 mL of Belzer MPS® perfusate (one bag) for two (2) human kidneys.
Belzer MPS® is a clear to straw-colored solution for the in-vitro flushing and temporary continuous perfusion preservation of explanted kidneys. This solution is consistent with an extracellular solution, based on its sodium/potassium ratio. This solution has a calculated potassium concentration of 25 mEq/L, a sodium concentration of 100 mEq/L, an osmolarity of 300 mosmol/kg, and a pH of approximately 7.4 at 20°C.
Belzer MPS® solution should be stored between 2°- 25°C (36°- 77°F). While 5°C is the ideal temperature for actual perfusion of Belzer MPS®, a range of 4°- 8°C is acceptable. Do not freeze or expose to excessive heat.
PREPARATION AND ADMINISTRATION
Remove overwrap prior to use. Inspect perfusate to ensure there is no particulate matter, precipitates or contamination in the perfusate. If the perfusate is clear and no particulate is observed, the perfusate is safe to use.
NOTE: If the perfusate contains any particulate, contact Bridge to Life Ltd. to make arrangements to return.
Pre-cool the kidney by vascular flush-out using Belzer MPS® or other cooled solutions (2°-8°C) (Belzer UW® Cold Storage Solution, Ringers, or saline). The kidney can then be placed into a perfusion apparatus that is capable of maintaining temperature within the range of 2°-8°C. The kidney should be perfused following the manufacturer’s or perfusion center’s protocol. Belzer MPS® is suitable for a mean perfusion time of 29 hours ±8 hours.1 Belzer MPS® should be flushed from the donor organ at the time of implantation.
For further information regarding clinical experience with organ preservation solutions, please contact the company for a bibliography of organ preservation articles.
Possible additives, recommended by the University of Wisconsin include: Penicillin (150,000 units), Regular Insulin (40 units) and Dexamethasone (8 mg). The use of these additives is not required but rather is at the discretion of the Organ Procurement or Transplant professional.
Belzer MPS® is made with Hydroxyethyl Starch, which has been the cause of hypersensitivity reactions in patients. Also, if applicable, penicillin, insulin and dexamethasone have caused hypersensitivity reactions in patients. Physicians should be prepared to respond to possible reactions.
NOT INTENDED FOR SYSTEMIC ADMINISTRATION BY DIRECT INJECTION OR INTRAVENOUS INFUSION.
NOT FOR IN SITU FLUSHING OF ORGANS IN LIVING DONORS OR PATIENTS.
DO NOT RE-USE. RE-USE OF TRANSPLANT SOLUTION MAY CAUSE INFECTION OR SEROLOGICAL CROSS CONTAMINATION.
|CONSTITUENT||AMOUNT/1000 ML||CONCENTRATION (mmol/L)|
|Adenine (free base)||0.68 g||5|
|Calcium Chloride (dihydrate)||0.068 g||0.5|
|Dextrose (+)||1.80 g||10|
|Glutathione (reduced)||0.92 g||3|
|HEPES (free acid)||2.38 g||10|
|Hydroxyethyl Starch||50.0 g||N/A|
|Magnesium Gluconate||1.13 g||5|
|Potassium Phosphate (monobasic)||3.4 g||25|
|Ribose, D(-)||0.75 g||5|
|Sodium Gluconate||17.45 g||80|
|Sodium Hydroxide||0.70 g||N/A|
|Sterile Water for Injection||To 1000 mL Volume||N/A|
When Belzer MPS® solution is used as described, no adverse reactions attributed to the solution have been observed.
Federal and certain international laws restrict the sale of Belzer MPS® to the order of a physician or a licensed practitioner.
Preservation Solutions, Inc.
1099 Proctor Drive
Elkhorn, WI 53121
Bridge to Life Ltd.
128 Suber Rd
Columbia, SC 29210-3851
(1) WH Barber et. al.: Comparison of Simple Hypothermic Storage, Pulsatile Perfusion with Belzer’s Gluconate-Albumin Solution, and Pulsatile Perfusion with UW Solution for Renal Allograft Preservation. Transplantation Proceedings, Vol. 23, No. 5 (October), 1991; pp 2394-2395
Belzer MPS® is a trademark of the Wisconsin Alumni Research Foundation (WARF) used under an exclusive license granted to Bridge to Life Ltd.